Peter J. Reddig

Array ( [id] => 18361440 [patent_doc_number] => 20230143031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => ENGINEERED T CELL RECEPTORS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/904941 [patent_app_country] => US [patent_app_date] => 2021-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23200 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -96 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18752490 [patent_doc_number] => 20230355745 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => CORONAVIRUS-DERIVED RECEPTOR-BINDING DOMAIN VARIANT HAVING REDUCED ACE2-BINDING AFFINITY AND VACCINE COMPOSITION COMPRISING THE SAME [patent_app_type] => utility [patent_app_number] => 18/044365 [patent_app_country] => US [patent_app_date] => 2021-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15875 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044365 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17363571 [patent_doc_number] => 11230588 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-25 [patent_title] => CD80 variant immunomodulatory proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 17/161584 [patent_app_country] => US [patent_app_date] => 2021-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 34 [patent_no_of_words] => 122537 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17161584 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16822760 [patent_doc_number] => 20210138053 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => ANTI-TUMORAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/152031 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3641 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17152031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18230424 [patent_doc_number] => 20230069418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => METHOD AND ANTIBODY FOR DETECTION OF HBCAG [patent_app_type] => utility [patent_app_number] => 17/791415 [patent_app_country] => US [patent_app_date] => 2021-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17471 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16853438 [patent_doc_number] => 20210154183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => IMMUNOTHERAPEUTIC DOSING REGIMENS COMPRISING POMALIDOMIDE AND AN ANTI-CS1 ANTIBODY FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/150099 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762360 [patent_doc_number] => 20210107941 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 17/123936 [patent_app_country] => US [patent_app_date] => 2020-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35035 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17123936 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18178301 [patent_doc_number] => 20230039030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => CHIMERIC ANTIGEN RECEPTORS THAT BIND TO PROSTATE SPECIFIC MEMBRANE ANTIGEN [patent_app_type] => utility [patent_app_number] => 17/788723 [patent_app_country] => US [patent_app_date] => 2020-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8975 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17788723 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18164691 [patent_doc_number] => 20230031287 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => METHOD AND COMPOSITION FOR ENHANCING THE IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 17/784891 [patent_app_country] => US [patent_app_date] => 2020-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17389 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17784891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16728148 [patent_doc_number] => 20210095295 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 17/117368 [patent_app_country] => US [patent_app_date] => 2020-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14222 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17117368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17713676 [patent_doc_number] => 11377660 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-05 [patent_title] => Chimeric antigen receptors targeting B-cell maturation antigen [patent_app_type] => utility [patent_app_number] => 17/117335 [patent_app_country] => US [patent_app_date] => 2020-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 39 [patent_no_of_words] => 14326 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17117335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16793246 [patent_doc_number] => 20210123063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 17/117311 [patent_app_country] => US [patent_app_date] => 2020-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17117311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16946602 [patent_doc_number] => 20210205293 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => COMBINATION OF TOPOISOMERASE-I INHIBITORS WITH IMMUNOTHERAPY IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/115219 [patent_app_country] => US [patent_app_date] => 2020-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17866 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17115219 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16883736 [patent_doc_number] => 20210169931 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection [patent_app_type] => utility [patent_app_number] => 17/115360 [patent_app_country] => US [patent_app_date] => 2020-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8075 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17115360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18207530 [patent_doc_number] => 20230053787 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => METHODS RELATED TO TOXICITY AND RESPONSE ASSOCIATED WITH CELL THERAPY FOR TREATING B CELL MALIGNANCIES [patent_app_type] => utility [patent_app_number] => 17/782584 [patent_app_country] => US [patent_app_date] => 2020-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 119724 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -94 [patent_words_short_claim] => 201 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782584 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18108129 [patent_doc_number] => 20230001009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => NANOPARTICLE COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/781945 [patent_app_country] => US [patent_app_date] => 2020-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15587 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17781945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20150483 [patent_doc_number] => 20250250321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-07 [patent_title] => Multifunctional Multispecific Multimeric Biomolecule Polymer Having Prolonged In-Vivo Duration [patent_app_type] => utility [patent_app_number] => 17/780565 [patent_app_country] => US [patent_app_date] => 2020-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8652 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17619000 [patent_doc_number] => 11338027 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-24 [patent_title] => Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer [patent_app_type] => utility [patent_app_number] => 17/104786 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 77 [patent_figures_cnt] => 76 [patent_no_of_words] => 74277 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17104786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18094614 [patent_doc_number] => 20220412955 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => A MODEL OF CLINICAL SYNERGY IN CANCER [patent_app_type] => utility [patent_app_number] => 17/779870 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22714 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 215 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20466625 [patent_doc_number] => 12522658 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-13 [patent_title] => Anti-CD79 chimeric antigen receptors, CAR-T cells, and uses thereof [patent_app_type] => utility [patent_app_number] => 16/950296 [patent_app_country] => US [patent_app_date] => 2020-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 69 [patent_figures_cnt] => 69 [patent_no_of_words] => 54255 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950296 [rel_patent_id] =>[rel_patent_doc_number] =>)